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Abstract
Background Hereditary angioedema due to C1 inhibitor deficiency (HAE-1/2) is a chronic and debilitating disease. The
unpredictable clinical course represents a significant patient burden.
Objective To analyse longitudinal registry data from the Icatibant Outcome Survey (IOS) in order to characterize tem-
poral changes in disease activity in patients with HAE-1/2.
Methods Icatibant Outcome Survey (NCT01034969) is an international observational registry monitoring the clinical
outcomes of patients eligible for icatibant treatment. The current analyses are based on data collected between July
2009 and July 2019. Retrospective data for attacks recorded in the 12 months prior to IOS enrolment and for each 12-
month period up to 7 years were analysed.
Results Included patients reported angioedema attacks without long-term prophylaxis (LTP; n = 315) and with LTP
(n = 292) use at the time of attack onset. Androgens were the most frequently used LTP option (80.8%). At the popula-
tion level, regardless of LTP use, most patients (52–80%) reporting <5 attacks in Year 1 continued experiencing this rate;
similarly, many patients (25–76%) who reported high attack frequency continued reporting ≥10 attacks/year. However,
year on year, 31–51% of patients experienced notable changes (increase/decrease of ≥5 attacks) in annual attack fre-
quency. Of patients who reported an absolute change of ≥10 attacks from Year 1 to 2, 17–50% continued to experience
a change of this magnitude in subsequent years.
Conclusion At the population level, attack frequency was generally consistent over 7 years. At the small group level,
28.8–34.5% of patients reported a change in attack frequency of ≥5 attacks from Year 1 to Year 2; up to half of these
patients continued to experience this magnitude of variation in disease activity in later years, reflecting high intra-patient
variability.
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Introduction
Hereditary angioedema with C1 inhibitor deficiency (HAE-1/2) is
a rare condition caused by mutations of the SERPING1 gene.
Patients experience unpredictable attacks characterized by vascular
oedema in mucosal/submucosal or deep dermal/subcutaneous tis-
sues.1,2 Initial symptom onset typically occurs during the first two
decades, with patients experiencing recurrent attacks over their
lifetime.3,4 The unpredictable nature of angioedema attacks places
a considerable psychological and socioeconomic burden on the
patient.5,6 Severity of these attacks can range from mild to severe,
with unpredictable disabling effects on activities of daily living4,6;
furthermore, laryngeal attacks are life-threatening or fatal if imme-
diate treatment is not obtained.7
Therapy options for HAE-1/2 focus on treating the attack as it
occurs (acute or on-demand treatment) or by providing either
pre-procedural or long-term prophylaxis (LTP) to mitigate the risk
of an attack.8 Significant developments have been made in the
understanding of disease pathophysiology during the last dec-
ade.9,10 Additionally, advances from treatments exclusively admin-
istered in a clinical setting to self-treatment at home became
possible through the introduction of innovative therapies and
patient education programmes,11,12 considerably improving the
health-related quality of life of patients with HAE-1/2.13,14
HAE-1/2 is widely held to show considerable variation in dis-
ease activity not only between patients but also within patients
over time.15–17 Very few recent publications have described the
broader clinical picture of how disease activity may manifest and
fluctuate (e.g. patients may be free of attacks for years, but then
suddenly and without warning may experience a fatal attack).
Because of this, the variability of disease is largely unknown. A
better understanding of the course of HAE-1/2 over time would
be of benefit to patients and healthcare providers alike. Observa-
tional drug registries and prospective studies, particularly those
involving rare diseases, are an important source of real-world
information about the course of a disease.18,19 Here, we report
longitudinal data from the Icatibant Outcome Survey (IOS), an
international registry of patients diagnosed with HAE-1/2 (and
other forms of angioedema) who are eligible to receive icatibant
to treat their attacks, in order to better characterize the course of
HAE-1/2.
Materials and methods
Study design and patients
Icatibant Outcome Survey (ClinicalTrials.gov, NCT01034969) is
a prospective observational registry; detailed methodology has
been published elsewhere.20 The analyses described herein are
based on data collected between July 2009 and July 2019 in
patients with HAE-1/2. Retrospective data for attacks recorded
in the 12 months prior to IOS enrolment and for each 12-
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month period up to 7 years were analysed. A total of 56 centres
in 12 countries (Austria, Brazil, Czech Republic, Denmark,
France, Germany, Greece, Israel, Italy, Spain, Sweden, and the
United Kingdom) contributed to this analysis. Patient demo-
graphics and characteristics were recorded at enrolment (IOS
entry), including information on HAE attacks before IOS entry,
and at routine visits thereafter, recommended to take place
approximately every 6 months.
Attack data were captured as previously described.20,21 Attack
severity was classified as very mild (very mild interference with
daily activities), mild (mild interference with daily activities),
moderate (moderate interference with daily activities and no
other countermeasures required), severe (severe interference
with daily activities and with or without other countermea-
sures), and very severe (very severe interference with daily activi-
ties and other countermeasures required). Treated attacks were
defined as those receiving acute treatment with icatibant,
whereas untreated attacks were defined as those that did not
receive any acute treatment. Separate analyses were conducted
depending on whether patients were receiving LTP or not at the
recorded time of attack onset. No patients were censored, and
the same patient may appear in both categories if their use of
LTP was initiated, temporarily interrupted or permanently dis-
continued during follow-up, and if they experienced attacks at
different times both without and with LTP.
Icatibant Outcome Survey is conducted in accordance with
the Declaration of Helsinki and the International Conference on
Harmonisation Good Clinical Practice Guidelines. Approval was
obtained from ethics committees and/or local health authorities
at all centres.
Statistical analyses
Longitudinal analyses of attack frequency and severity and year-
on-year change in disease activity were performed at the popula-
tion level for each 12-month period from enrolment to 7 years
after IOS entry. Small group-level data analyses were conducted
to resemble individual patient-level data analyses. Firstly,
patients were grouped into three categories based on their attack
frequency in Year 1 of IOS follow-up: <5 attacks per year (‘low
frequency’); 5 to <10 attacks per year (‘moderate frequency’);
and ≥10 attacks per year (‘high frequency’). Secondly, the same
three categories were used to define absolute change (increase or
decrease) in attack frequency compared with the previous year
of follow-up (e.g. change from Year 1 to Year 2); an absolute
change of <5 attacks from year to year was considered to be a
sign of relatively consistent disease activity (‘no notable
change’), and changes of 5 to <10 attacks and ≥10 attacks from
year to year were considered to be ‘moderate’ and ‘substantial’
changes, respectively, in disease activity. Data are presented as
median (range) or mean (SD) and proportions of patients per
annual attack frequency/absolute change category.
Results
At the population level, the number and severity of attacks
per year do not change substantially over time
The analysis population comprised 315 patients who reported
attacks without LTP and 292 patients who reported attacks with
LTP during follow-up (Table 1). The majority of patients were
diagnosed with HAE Type I and were female. The median (Q1,
Q3) delay in diagnosis was 6.4 (0.3, 18.1) years in patients with
no prior LTP and 6.6 (0.5, 17.5) years in those with prior LTP.
The most frequently received prior LTP was attenuated andro-
gens (80.8%), followed by tranexamic acid (40.1%) and plasma-
derived C1-INH (26.4%).
The median number of all attacks, untreated attacks and
icatibant-treated attacks per patient per year did not change sig-
nificantly (P ≥ 0.05), irrespective of the LTP used (Fig. 1). There
were no substantial differences in attack frequency between male
and female patients (Table S1, Supporting Information). Mean
(standard deviation) number of attacks (overall, untreated and
icatibant-treated) were reported in Table S2 (Supporting Infor-
mation). Categorizing patients into three attack frequency
groups (<5, 5 to <10 and ≥10 attacks per year) confirmed that
disease activity was generally consistent at the population level
(Fig. S1, Supporting Information). Attack severity (prior to icat-
ibant treatment) was generally similar over time, with and with-
out LTP; however, slightly higher proportions of patients with
LTP had very severe attacks during most years (Fig. 2).
At the small group level, annual attack frequency, grouped
by Year 1 rate, suggests that most patients who report
either low (<5) or high (≥10) annual attack rate continue to
experience these frequencies
Most patients (52–80%) with <5 attacks in Year 1 continued to
experience low attack frequency in subsequent years (Fig. 3);
similarly, 25–76% of patients with ≥10 attacks in Year 1 contin-
ued to experience high annual attack frequency. For patients
who reported 5 to <10 attacks in Year 1, annual attack frequency
during subsequent years was variable. There was a general trend
towards lower annual attack frequency in patients with LTP
compared with those without LTP in the low- and moderate-
frequency groups, but not in the high-frequency group.
Absolute change in attack frequency from year to year
indicates that up to half of the patients without LTP and up
to one-third of patients with LTP experience fluctuating
disease activity
Fluctuations in annual attack frequency were evaluated, with
change categorized as a difference of <5, 5 to <10 or ≥10 attacks
from the previous year (Fig. 4).
In patients without LTP, 35% experienced moderate (five to
<10) or substantial (≥10) changes in the number of attacks from
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Year 1 to Year 2; in the subsequent years, this proportion varied
between 31% and 51%. In patients with LTP, the proportion
reporting no notable change was slightly higher and more con-
sistent than in patients without LTP, whereas the proportion
reporting a substantial change was generally lower at each time
point.
Absolute change in attack frequency, grouped by
difference from Year 1 to Year 2, suggests that patients
with a notable change after the first year continue to
experience fluctuating disease activity
Between 43% and 80% of patients without a notable change in
attack frequency from Year 1 to Year 2 continued to report little
change in subsequent years; 43–70% of patients without LTP
and 52–80% of patients with LTP continued to report no nota-
ble change (Fig. 5). Patients with a change of five to <10 attacks
from Year 1 to Year 2 experienced variable changes in attack fre-
quency in subsequent years, particularly those without LTP; the
number of patients per year in this category was small (n ≤ 17).
The absolute change in attack frequency was particularly incon-
sistent for patients without LTP, for whom changes of five or
more attacks from year to year ranged from 50% to 77% up to
Year 5. Between 17% and 50% of patients with an absolute
change of ≥ 10 attacks from Year 1 to 2 continued to experience
a substantial change up to Year 6; again, the number of patients
per year in this category was small (n ≤ 14).
Discussion
This is the first report of longitudinal IOS data, without refer-
ence to icatibant treatment outcomes, to characterize the vari-
ability of disease in a large international cohort of patients with
HAE-1/2. The initial onset of clinical symptoms in this cohort,
during early to late adolescence, is consistent with previous non-
IOS studies in patients with HAE-1/2.15,17,22,23 The high variabil-
ity in attack frequency observed in many IOS patients is general-
izable to the wider population of patients with HAE-1/2,4 and
reflects the need for patients and physicians to continually evalu-
ate disease activity and ensure that acute treatment can be
accessed and LTP, when needed, is optimized.
At the population level, the frequency and severity of attacks
per patient per year following IOS enrolment were generally
consistent over the 7-year analysis period, confirming the
chronic nature of the disease. Categorizing patients by their
attack frequency in Year 1 and absolute change into Year 2
allowed small group-level analyses that could infer outcomes
comparable with individual patient-level data analyses. An abso-
lute change (increase or decrease) of five or more attacks during
Year 1 was experienced by approximately one-third of the
patients. Use of LTP did not mitigate this fluctuation in disease
activity in a consistent manner over time. Of these patients,
between one-third and one-half continued to experience moder-
ate or substantial changes in annual attack frequency for the next
5 years. In contrast, most patients with an absolute change of <5
attacks in Year 1 showed little change in attack frequency during
the subsequent 3 years; however, greater proportions of patients
reported changes of five or more attacks in the last 2 years of
Table 1 Patient demographics and disease characteristics at IOS









HAE diagnosis, n (%)
Type 1 292 (92.7) 280 (95.9)
Type 2 23 (7.3) 12 (4.1)
Sex, n (%)
Female 201 (63.8) 164 (56.2)
Male 114 (36.2) 128 (43.8)
Age at enrolment, years
n (missing) 315 (0) 292 (0)
Median (Q1, Q3) 38.4 (26.0, 51.0) 39.5 (28.3, 50.8)
Min, max 16.4, 81.3 15.3, 80.3
Age at onset of symptoms, years
n (missing) 277 (38) 241 (51)
Median (Q1, Q3) 13.0 (6.0, 19.0) 10.0 (5.0, 18.0)
Min, max 0.2, 72.0 0.2, 67.0
Age at diagnosis, years
n (missing) 303 (12) 266 (26)
Median (Q1, Q3) 21.1 (13.1, 34.6) 20.7 (13.6, 32.3)
Min, max 0.0, 74.2 0.0, 69.2
Delay between onset of symptoms and diagnosis, years
n (missing) 275 (40) 234 (58)
Median (Q1, Q3) 6.4 (0.3, 18.1) 6.6 (0.5, 17.5)
Min†, max 19.0, 61.0 41.8, 66.9
Countries with ≥10% of enrolled patients in either LTP subgroup,
n (%)
France 64 (20.3) 97 (33.2)
Germany 56 (17.8) 11 (3.8)
Spain 49 (15.6) 62 (21.2)
UK 37 (11.7) 54 (18.5)
Type of LTP received†, n (%)
Attenuated androgens† 236 (80.8)
Tranexamic acid 117 (40.1)
Plasma-derived C1-INH† 77 (26.4)
Recombinant C1-INH 6 (2.1)
C1-INH (unspecified form) 2 (0.7)
Other 50 (17.1)
C1-INH, C1 inhibitor; HAE, hereditary angioedema; IOS, icatibant outcome
survey; LTP, long-term prophylaxis; max, maximum; min, minimum; Q, quar-
tile.
† Negative delay determined in patients diagnosed before symptoms due to
family history. ‡Patients can be listed in more than one category if they use
different types of LTP during separate HAE attacks. §Danazol (n = 178,
61.0%), stanozolol (n = 50, 17.1%) or oxandrolone (n = 8, 2.7%). ¶Intra-
venously administered.
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follow-up. These results suggest that although disease activity
may be more or less consistent for many patients, those who
report a notable change in annual attack frequency may con-
tinue to experience changes of similar magnitude for several
years. Interestingly, we noted a higher number of untreated
attacks in the year prior to IOS entry (presumably when few
patients had access to icatibant and, thereby, self-administration
was more difficult) than in subsequent years.
Disease activity was generally as expected in patients experi-
encing attacks without and with LTP, with smaller proportions
of the ‘with LTP’ group reporting high annual frequency (≥10
attacks per year) or a substantial absolute change (≥10 attacks)
year on year, although there were trends towards greater propor-
tions of patients with LTP reporting very severe attacks. The lat-
ter finding is somewhat surprising (given that one of the aims of
LTP is to reduce attack severity),24 potentially highlighting
unmet needs with LTP agents available at the time of the survey.
Importantly, guidelines recommend that LTP is considered in all
severely symptomatic patients,2 and the subgroup of patients
reporting attacks with LTP may represent those with more sev-
ere underlying disease in the absence of any preventative treat-
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Figure 1 Median (range) number of (a) overall attacks, (b) untreated attacks and (c) icatibant-treated attacks per patient per year of
follow-up. The minimum number of attacks per patient per year at all time points was zero for treated and untreated attacks and one for
icatibant-treated attacks. n indicates the number of patients at each time point. Y1 begins at IOS entry and refers to the first year of
follow-up; pre-IOS refers to 12 months before IOS entry. Comparing the median number of attacks per year from Y2 to Y7 with Y1
(Wilcoxon signed-rank test), P ≥ 0.05 for all years and all subgroup categories. IOS, Icatibant Outcome Survey; LTP, long-term
prophylaxis; Y, Year.
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intermediate categories of moderate attack frequency (5 to <10
attacks in Year 1) or moderate absolute change (5 to <10 attacks
from Year 1 to 2) were more likely to report subsequent higher
attack frequency or higher absolute change, respectively, com-
pared with patients with LTP in the same categories. In line with
these findings, results from a study published in 2011 evaluating
Italian patients with HAE showed that patients receiving LTP
with androgens continued to experience attacks during the treat-
ment period, although the frequency of attacks was reduced
compared with previous periods without LTP.25
The unpredictable nature of HAE-1/2 is well known. In a
foundational review of the clinical course of 30 patients with
HAE, Frank et al.26 describe a great variability of attack fre-
quency where patients may have no attacks for long periods of
time, followed by many in rapid succession, as well as patients
who may have attacks every few weeks. A retrospective study of
209 German patients published in 2006 by Bork et al.15 reported
that although 158 (75.6%) did not have attack-free intervals of
>12 months, the remaining 51 patients had symptom-free peri-
ods for an average of 7.4 years; 36 of these patients were not
receiving prophylaxis and thus the attack-free periods were con-
sidered part of their natural disease course. Inter-patient vari-
ability in attack frequency was also noted by Bygum,27 Agostoni,
and Cicardi, Winnewisser et al. and Jolles et al.16,22,28 Although
this unpredictability from patient to patient has been widely
reported, the current findings provide new insights into intra-
patient variability. Although a number of life events and con-
comitant treatments have been identified as triggers for HAE
attacks,2 most attacks have no known trigger.29 Exposure to
unidentified triggers is likely to vary over time and may con-
tribute to the heterogeneity of disease activity. Consistent with
updated guideline recommendations for the management of
HAE, these data reflect the unpredictable course of the disease
over an individual patient’s lifetime and highlight the impor-
tance of (i) continual reassessment of disease activity and LTP at
each visit, (ii) patients carrying on-demand medication at all
times (including those receiving LTP), (iii) individualized action
plans and treatment plans and (iv) patient awareness of possible
attack triggers.2,24
The findings of this study should be interpreted in the context
of available LTP options during the follow-up period and treat-
ment patterns in the participating countries. A greater propor-
tion of patients in Germany reported having attacks without
LTP than with LTP, consistent with previous findings from IOS
that noted differing LTP treatment patterns in Germany com-
pared with patients from other IOS countries.30 The most com-
monly used LTP therapies in this study were attenuated
androgens and tranexamic acid, despite known risks with the
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Patients with LTPPatients without LTP
Figure 2 Population-level attack severity (icatibant-treated attacks only; severity recorded prior to treatment) per year. n indicates the
number of icatibant-treated attacks at each time point. Y1 begins at Icatibant Outcome Survey entry and refers to the first year of follow-
up. LTP, long-term prophylaxis; Y, Year.
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former and a lack of recommendation for the latter.31 Only a
quarter of patients were receiving intravenous plasma-derived
C1 inhibitor at the time of reported attack. Recent advances in
the availability of LTP options with improved efficacy, safety
and/or convenience, such as plasma kallikrein inhibitor lanade-
lumab and a subcutaneous formulation of C1 inhibitor,24 were











































































































































































































Patients with LTP usePatients without LTP use
Figure 3 Proportions of patients in three attack frequency categories (<5, 5 to <10 and ≥10 attacks per year) grouped by the number of
attacks in Y1. n indicates the number of patients at each time point. Y1 begins at Icatibant Outcome Survey entry and refers to the first
year of follow-up. LTP, long-term prophylaxis; Y, Year.
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not accounted for in this analysis. These newly available thera-
pies may have a greater impact on attack severity and frequency
than the LTP treatments most frequently used in this study.
The limitations of these analyses include the use of group-
level analyses to closely resemble outcomes of individual patient-
level analyses, which were not feasible using IOS data. Insights
into disease activity in paediatric patients would be of interest
because of increased attack rates observed during puberty;3 how-
ever, only nine patients <18 years of age contributed data, and a
robust subgroup analysis was not possible. The high number of
attacks recorded in the 12 months prior to IOS enrolment com-
pared with attacks while enrolled in IOS was driven by a large
number of untreated attacks for which an attack start date is not
known. Unlike icatibant-treated attacks, untreated attacks are
assumed to have occurred in that 12-month period; thus, this is
a limitation of this method of collecting retrospective data. Nev-
ertheless, attacks occurring during IOS enrolment, for which
attack start dates were generally available, clearly show that over
the 7-year period, the median number of attacks per patient per
year was generally consistent. However, individual patients may
experience unpredictable changes in attack frequency and/or
severity over time, including the occurrence of life-threatening
attacks. Use of LTP was only considered at the recorded time of
attack onset; some types of LTP may have a preventative effect
for a longer window of time, which was not accounted for in this
analysis. Further limitations are typical of registry-based studies
using data derived from patient recall, which may be open to
patient interpretation.
Conclusions
This study of longitudinal data from IOS aimed to characterize
the variability of disease activity in patients with HAE-1/2.
Although notable changes in attack frequency in the large overall
population were not observed, a deeper analysis at the small
group level provided novel insights into how the clinical course
of HAE-1/2 may fluctuate unpredictably for select patients.
Although attack frequency was consistent for some throughout
the 7-year follow-up period, up to one-half of patients without
LTP and up to one-third of patients with LTP experienced con-
siderable changes during the first year of IOS enrolment, with
many patients in these subgroups continuing to experience fluc-
tuating disease activity during subsequent years. These findings
highlight the importance of patients being provided with and
carrying acute treatment at all times and may help inform
patient and physician decisions regarding the management of
this unpredictable and chronic disease.




















































































































Change of ≥10 attacks Change of <5 attacksChange of 5 to <10 attacks
Patients with attacks with LTPPatients with attacks without LTP
Figure 4 Absolute change in attack frequency from year to year by category (<5, 5 to <10 and ≥10 attacks). n indicates the number of
patients at each time point; the same patient may be included in both the ‘without LTP’ and ‘with LTP’ groups for different attacks. Y1
begins at Icatibant Outcome Survey entry and refers to the first year of follow-up; Y1–Y2 refers to the absolute change in the number of
attacks from Y1 to Y2. LTP, long-term prophylaxis; Y, Year.
© 2021 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd
on behalf of European Academy of Dermatology and Venereology.
JEADV 2021
8 Maurer et al.





















































































































































































from Y1 to Y2
Patients with
change of ≥10




from Y1 to Y2
Change of ≥10 attacks Change of <5 attacksChange of 5 to <10 attacks
Patients with LTP usePatients without LTP use
Figure 5 Proportions of patients with absolute change in attacks from year to year, grouped by change in attack frequency during Y1–
Y2. n indicates the number of patients at each time point; the same patient may be included in both the ‘without LTP’ and ‘with LTP’
groups for different attacks. Y1 begins at Icatibant Outcome Survey entry and refers to the first year of follow-up; Y1–Y2 refers to the
absolute change in the number of attacks from Y1 to Y2. Numbers may not add up to 100% due to rounding. LTP, long-term prophylaxis;
Y, Year.
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Figure S1. Population-level attack frequency per year by cate-
gory (less than five, five to <10 and ≥10 attacks per year). n indi-
cates the number of patients at each time point.
Table S1. Median (IQR) number of overall attacks, untreated
attacks and icatibant-treated attacks per patient per year of fol-
low-up.
Table S2. Mean (SD) number of overall, untreated and icati-
bant-treated attacks per patient per year of follow-up.
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